- Top Workplaces
- Prelude Therapeutics
Prelude Therapeutics
We are a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Our diverse pipeline is
comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for
cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective
inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class
SMARCA2/BRM protein degrader.
comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for
cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective
inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class
SMARCA2/BRM protein degrader.
Vision
Through purposeful drug discovery, excellence, and rigor, we will build a leading, fully integrated company to deliver novel medicines to patients.
Additional Culture Details
At Prelude, we have created a culture that brings us together through our shared sense of purpose. We are driven to perform and are proud to be a part
of an organization that values the collective strength of our diverse and talented employees.
of an organization that values the collective strength of our diverse and talented employees.
Recent Awards
Company Snapshots
